Top Page
Bodycote
(LSE:BOY)
Bodycote (BOY) vs. iShares MSCI United Kingdom ETF (EWC)
Bodycote Business Overview & Revenue Model
Bodycote Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 757.10M | 802.50M | 743.60M | 615.80M | 598.00M |
| Gross Profit | 109.30M | 108.10M | 269.70M | 225.70M | 186.90M |
| EBITDA | 124.00M | 201.70M | 186.60M | 167.70M | 97.00M |
| Net Income | 20.00M | 85.60M | 73.70M | 59.50M | 400.00K |
Balance Sheet | |||||
| Total Assets | 1.07B | 1.14B | 1.17B | 1.07B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 19.10M | 45.20M | 37.20M | 39.30M | 30.70M |
| Total Debt | 150.90M | 96.90M | 136.60M | 156.20M | 128.80M |
| Total Liabilities | 397.50M | 344.40M | 385.70M | 384.40M | 428.60M |
| Stockholders Equity | 668.10M | 790.80M | 780.90M | 684.70M | 680.50M |
Cash Flow | |||||
| Free Cash Flow | 82.50M | 109.20M | 70.10M | 87.10M | 74.50M |
| Operating Cash Flow | 152.60M | 191.60M | 137.10M | 139.10M | 134.40M |
| Investing Cash Flow | -112.80M | -71.20M | -62.30M | -104.80M | -124.70M |
| Financing Cash Flow | -67.60M | -110.20M | -76.60M | -24.80M | -1.30M |
Bodycote Technical Analysis
Bodycote Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £5.23B | 22.47 | 23.50% | 1.46% | 0.64% | 4.92% | |
76 Outperform | £610.14M | 13.07 | 14.06% | 4.57% | -1.26% | 6.56% | |
74 Outperform | £561.72M | 28.80 | 16.39% | 177.81% | 3.13% | 24.54% | |
74 Outperform | £4.56B | 24.42 | 16.16% | 2.83% | -1.03% | 4.06% | |
74 Outperform | £6.52B | 20.91 | 17.83% | 1.28% | -4.95% | 36.95% | |
71 Outperform | £1.08B | 56.93 | 2.74% | 4.02% | -5.66% | -76.42% | |
65 Neutral | $10.82B | 15.59 | 5.20% | 1.89% | 3.09% | -26.84% |
Bodycote Corporate Events
Bodycote PLC has announced a significant change in its shareholder structure as FMR LLC, a Boston-based investment firm, has increased its voting rights in the company to 10.0027%. This acquisition of voting rights marks a substantial increase from the previous 5.78%, potentially impacting Bodycote’s corporate governance and strategic direction.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £980.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has completed the third tranche of its £30 million share buyback programme, purchasing 21,743 ordinary shares, which will be cancelled, leaving a total of 177,310,404 shares in issue. This move is part of a broader strategy to optimize capital structure and return value to shareholders, reflecting confidence in the company’s financial health and future prospects.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback program, purchasing 18,105 ordinary shares as part of an extended initiative. This move is part of a broader strategy to manage its capital structure and enhance shareholder value, having acquired a total of 14,072,256 shares since March 2024, reflecting the company’s commitment to returning value to its investors.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback program, purchasing 15,701 ordinary shares at an average price of 582.1958 pence per share. This move is part of an extended program that has seen the company buy back a total of 13,881,011 shares since March 2024, potentially signaling confidence in its financial health and aiming to enhance shareholder value.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback program, purchasing 27,288 ordinary shares at an average price of 562.7418 pence per share. This move is part of an extended program that has seen the company buy back a total of 13,38,123 ordinary shares since March 2024, reflecting its strategy to manage capital and enhance shareholder value.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback program, purchasing 31,337 ordinary shares at an average price of 565.1951 pence per share. This move is part of an extended program that began in December 2024, aiming to optimize the company’s capital structure and enhance shareholder value, with a total of 13,723,753 shares bought back since March 2024.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback programme, purchasing 38,679 of its own ordinary shares at an average price of 569.0436 pence per share. This move is part of an extended programme that has seen the company buy back a total of 13,692,416 shares since March 2024, which may impact the company’s market positioning by reducing the number of shares in circulation, potentially increasing shareholder value.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc announced the continuation of its share buyback program, purchasing 29,362 ordinary shares as part of its extended program. This move is part of a broader strategy to enhance shareholder value, having repurchased a total of 13,512,523 shares since March 2024, indicating a strong commitment to returning capital to shareholders and potentially improving market confidence.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote PLC has announced a change in its major holdings, with Martin Currie Investment Management Limited adjusting its voting rights in the company. The adjustment sees Martin Currie’s voting rights decrease from 5.27% to 4.96%, indicating a slight reduction in their stake. This change could potentially impact Bodycote’s shareholder dynamics and influence future decision-making processes within the company.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £890.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote’s recent trading update reveals a 6% decline in group revenue for the first four months of 2025 compared to the previous year, attributed to strong prior year comparators and reduced energy surcharges. Despite challenges in the Automotive and Industrial markets, the company has seen improvements in Civil Aerospace and Defence sectors. Bodycote is advancing its ‘Optimise, Perform & Grow’ strategy, aiming to enhance operational efficiency and resilience, with plans to expand its plant and overhead reduction program. The company anticipates a second-half weighted improvement in adjusted operating profit, driven by new contracts in Defence and Oil & Gas, as well as growth in Aerospace & Defence.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc announced that all resolutions proposed at its Annual General Meeting on May 21, 2025, were approved by shareholders. The resolutions included the re-election of board members, approval of the directors’ remuneration policy, and the renewal of authorities related to share capital management. The successful passage of these resolutions reflects shareholder confidence in the company’s governance and strategic direction, potentially strengthening Bodycote’s market position and operational stability.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the appointment of Emmanuelle Dubu as a Non-Executive Director, effective June 23, 2025. Dubu, with extensive experience in international engineering and leadership roles, will join the Remuneration, Nomination, and Audit committees. Her background in metallurgy and international industry experience is expected to contribute significantly to Bodycote’s board. Additionally, Lili Chahbazi has been appointed as the Senior Independent Director, succeeding Patrick Larmon, who will step down from the board in September 2025. These changes reflect Bodycote’s strategic focus on strengthening its leadership team to enhance its market position and stakeholder engagement.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback programme, purchasing 1,397 ordinary shares at an average price of 533.515 pence per share. This move is part of an extended programme that has seen the company buy back a total of 12,712,626 shares, aiming to cancel these shares and reduce the number of shares in circulation, which could potentially enhance shareholder value by increasing earnings per share.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the purchase and cancellation of 122,951 ordinary shares as part of its ongoing share buyback programme. This move is part of an extended programme that has seen the company buy back a total of 12,602,072 shares, aiming to optimize its capital structure and potentially enhance shareholder value.
Bodycote plc announced the continuation of its share buyback programme, purchasing 37,485 ordinary shares at an average price of 482.8736 pence per share. This move is part of an extended programme aimed at reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares and enhancing shareholder value. Following this transaction, Bodycote has a total of 179,142,288 ordinary shares in issue, with no shares held in treasury. This strategic financial maneuver is expected to strengthen Bodycote’s market position and demonstrate its commitment to returning value to shareholders.
Bodycote plc has announced the purchase and cancellation of 177,715 of its ordinary shares as part of its extended share buyback programme. This move is part of a broader strategy to manage the company’s capital structure, having acquired a total of 12,276,399 shares since March 2024, which may impact shareholder value and market perception.
Bodycote PLC announced that its Chief Financial Officer, Ben Fidler, has exercised shares under the Bodycote Incentive Plan. A total of 63,906 shares were exercised, with 29,835 shares sold to cover tax liabilities and 34,071 shares retained. This transaction reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Bodycote PLC announced that its CEO, Jim Fairbairn, exercised shares from the Bodycote Incentive Plan granted in 2024. The transaction involved exercising 94,139 shares, with 43,949 sold to cover tax liabilities and 50,190 retained, highlighting a strategic financial decision by the company’s leadership.
Bodycote plc has announced the performance targets for its Bodycote Incentive Plan (BIP) for 2025, following the release of its 2024 Annual Report. The targets include metrics for Return on Capital Employed, Earnings Per Share growth, and CO2 emissions reduction, reflecting the company’s commitment to financial performance and sustainability goals. These measures are expected to align with Bodycote’s strategic objectives and enhance its market position, potentially impacting shareholder value and environmental performance.
Bodycote plc has released its 2024 Annual Report and Accounts along with the notice for the 2025 Annual General Meeting. These documents are available for inspection on the National Storage Mechanism and the company’s website. The announcement underscores Bodycote’s commitment to transparency and regulatory compliance, potentially impacting investor confidence and stakeholder engagement.
Bodycote plc has announced the purchase of 43,776 of its own ordinary shares as part of its extended share buyback programme, with the intention to cancel these shares. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, reflecting confidence in its financial position and future prospects.
Bodycote plc has announced a continuation of its share buyback programme, purchasing 43,525 of its ordinary shares at prices ranging from 455.4p to 482.2p per share. This move is part of an extended programme that began in December 2024, with the company having bought a total of 11,796,983 shares since March 2024. The purchased shares will be canceled, reducing the total number of shares in issue to 179,659,189, which could potentially enhance shareholder value by increasing earnings per share.
Bodycote plc has announced the purchase of 44,761 of its ordinary shares as part of its extended share buyback program. This move, which is part of a larger strategy that has seen the company repurchase over 11 million shares since March 2024, aims to reduce the number of shares in circulation, potentially enhancing shareholder value and reflecting confidence in the company’s financial health.